About ciltacabtagene autoleucel
BCMA-directed CAR T-cell therapy
Used for
- Treats adults with relapsed or refractory multiple myeloma after at least one previous treatment line, including a proteasome inhibitor and immunomodulatory drug.
Usual adult dose
One intravenous infusion of 0.5–1.0 × 10⁶ CAR-positive viable T cells/kg, up to 1 × 10⁸ cells, after lymphodepleting chemotherapy.
Common side effects
- Cytokine release syndrome
- Low blood-cell counts and infections
- Neurologic problems, including confusion or difficulty speaking
- Low immunoglobulin levels
Important warnings
- Can cause life-threatening cytokine release syndrome and neurologic toxicity.
- Serious infections and prolonged low blood-cell counts can occur.
- Requires specialized monitoring and restricted distribution through certified treatment centers.
- Secondary cancers, including T-cell malignancies, have been reported.
Pregnancy
May harm an unborn baby; pregnancy testing and contraception are required around treatment. The effects on fertility are unknown.
Breastfeeding
Breastfeeding is not recommended during treatment; safety is unknown.
Interactions
- Live vaccines are not recommended around treatment.
- Other medicines that suppress immunity may increase infection risk or affect treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.